Save information for later
Sign Up

Learn About Metachromatic Leukodystrophy

What is the definition of Metachromatic Leukodystrophy?

Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. This accumulation especially affects cells in the nervous system that produce myelin, the substance that insulates and protects nerves. Nerve cells covered by myelin make up a tissue called white matter. Sulfatide accumulation in myelin-producing cells causes progressive destruction of white matter (leukodystrophy) throughout the nervous system, including in the brain and spinal cord (the central nervous system) and the nerves connecting the brain and spinal cord to muscles and sensory cells that detect sensations such as touch, pain, heat, and sound (the peripheral nervous system).

What are the causes of Metachromatic Leukodystrophy?

Most individuals with metachromatic leukodystrophy have mutations in the ARSA gene, which provides instructions for making the enzyme arylsulfatase A. This enzyme is located in cellular structures called lysosomes, which are the cell's recycling centers. Within lysosomes, arylsulfatase A helps break down sulfatides.

How prevalent is Metachromatic Leukodystrophy?

Metachromatic leukodystrophy is reported to occur in 1 in 40,000 to 160,000 individuals worldwide. The condition is more common in certain genetically isolated populations: 1 in 75 in a small group of Jews who immigrated to Israel from southern Arabia (Habbanites), 1 in 2,500 in the western portion of the Navajo Nation, and 1 in 8,000 among Arab groups in Israel.

Is Metachromatic Leukodystrophy an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Metachromatic Leukodystrophy Local Doctors?
Ingeborg Mann-Krageloh
Elite in Metachromatic Leukodystrophy
Elite in Metachromatic Leukodystrophy
Tuebingen, BW, DE 

Ingeborg Mann-Krageloh practices in Tuebingen, Germany. Ms. Mann-Krageloh is rated as an Elite expert by MediFind in the treatment of Metachromatic Leukodystrophy. Her top areas of expertise are Metachromatic Leukodystrophy, Leukodystrophy, CACH Syndrome, Pontocerebellar Hypoplasia, and Bone Marrow Transplant.

Elite in Metachromatic Leukodystrophy
Elite in Metachromatic Leukodystrophy
Milan, IT 

Francesca Fumagalli practices in Milan, Italy. Ms. Fumagalli is rated as an Elite expert by MediFind in the treatment of Metachromatic Leukodystrophy. Her top areas of expertise are Metachromatic Leukodystrophy, Leukodystrophy, CACH Syndrome, Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Metachromatic Leukodystrophy
Elite in Metachromatic Leukodystrophy
Tuebingen, BW, DE 

Samuel Groeschel practices in Tuebingen, Germany. Mr. Groeschel is rated as an Elite expert by MediFind in the treatment of Metachromatic Leukodystrophy. His top areas of expertise are Metachromatic Leukodystrophy, Leukodystrophy, CACH Syndrome, Pontocerebellar Hypoplasia, and Bone Marrow Transplant.

What are the latest Metachromatic Leukodystrophy Clinical Trials?
MATRIX - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia

Summary: This study is a national, non-randomized, open-label, multi-site with minimal risk study in adult with adrenomyeloneuropathy (AMN), childhood and adult subjects with cerebral ALD (cALD), juvenile/adult metachromatic leukodystrophy (MLD) and adults with leukoencephalopathy and axonal spheroids and pigmented glia (ALSP). 49 subjects will be enrolled with one blood sample collection during one of the...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells

Summary: The primary objective of the study is to determine the safety and feasibility of intrathecal administration of DUOC-01 as an adjunctive therapy in patients with inborn errors of metabolism who have evidence of early demyelinating disease in the central nervous system (CNS) who are undergoing standard treatment with unrelated umbilical cord blood transplantation (UCBT). The secondary objective of t...

Who are the sources who wrote this article ?

Published Date: June 29, 2021
Published By: National Institutes of Health